Pfizer’s head of vaccine research, Kathrin Jansen, said in a statement that while current data showed that boosters against the original Covid strain continued to protect against severe outcomes with Omicron, the company was acting out of caution.
“We recognise the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future,” she said.
Uğur Şahin, chief executive of the German biotech company BioNTech, added the protection of the original vaccine against mild and moderate Covid appeared to wane more rapidly against Omicron.
“This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but longer duration of protection.”
The trial will involve 1,420 people aged 18-55.
A spokesperson for Pfizer said that it did not include people older than 55 because the goal of the study was to examine the immune response of participants dosed, rather than estimate vaccine efficacy.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Covid-19 News Click Here
